The Pharma Data

MARCH 23, 2021

(NYSE: PFE) announced today that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2, the virus that causes COVID-19.

Virus 52

Virus Vaccine Hospitals Pharmacokinetics 52

Agency IQ

DECEMBER 1, 2023

It also stated that companies should consider whether an investigational product might interact with an administered vaccine for Covid-19. Regarding vaccination status: The new document expands upon a previously simple recommendation to determine vaccination status for patients enrolled in clinical trials.

FDA 40

FDA Clinical Trials Vaccine Drugs 40

The Pharma Data

DECEMBER 23, 2020

The parties also agreed to develop scientific and business relations and explore the possibilities for joint use of the Sputnik V vaccine and the AZD1222 vaccine in order to create more effective and long-term immunization against potential new coronavirus infections. Most Read Today. Source link.

Licensing 52

Licensing Licensing Vaccine Drugs 52

The Pharma Data

SEPTEMBER 15, 2020

Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. New stability, immunogenicity, and tolerability data for COVID-19 vaccine candidate, BNT162b2, presented. BNT162 mRNA-based Vaccine Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

APRIL 16, 2021

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. Due to the rapidly evolving and geographically diverse nature of the SARS-CoV-2 virus, continued scientific innovation remains critical to develop additional treatments. In the U.S.,

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

JULY 23, 2021

Ronapreve is a combination of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed to block infectivity of SARS-CoV-2, the virus that causes COVID-19. As soon as the novel SARS-CoV-2 virus was sequenced in early 2020, we got to work.

Treatment 52

Treatment Virus Clinical Trials Pharmaceuticals 52

The Pharma Data

APRIL 7, 2021

The addition of the SC administration also offers people living with MS another option at a time when they are being encouraged to discuss considerations around COVID-19 vaccination and their MS treatment with their physicians. Patients who have all three risk factors have the highest risk of developing PML.

Clinical Trials 52

Clinical Trials Treatment Virus Pharmacokinetics 52

Agency IQ

AUGUST 16, 2024

Likewise, it still omits radiopharmaceuticals, cancer vaccines, cell and gene therapy products, and microbiota-related products from its scope. Pharmacokinetic (PK) sample and analysis planning: Generally, the recommendations in the final guidance are nearly identical to those contained in the draft, with a few exceptions.

Production 40

Production FDA Science Clinical Trials 40

The Pharma Data

JANUARY 26, 2021

BLAZE-4 Additionally, initial results from the ongoing BLAZE-4 trial provide viral load and pharmacodynamic/pharmacokinetic data which demonstrated lower doses, including bamlanivimab 700 mg and etesevimab 1400 mg together, are similar to bamlanivimab 2800 mg and etesevimab 2800 mg together. patients who recovered from COVID-19. .

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

MARCH 5, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Treatment 40

Treatment Hospitals Long-Term Care Facilities Therapies 40

The Pharma Data

MAY 4, 2021

” “Even as the world makes progress on vaccine roll-outs, it remains vital for treatments to be available that can make a meaningful difference for those fighting COVID-19,” said David A. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

MARCH 11, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Hospitals 40

Hospitals Trials Long-Term Care Facilities Treatment 40

The Pharma Data

APRIL 7, 2022

announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). NYSE: PFE) and ReViral Ltd.

Virus 52

Virus Vaccine Clinical Development Hospitals 52

The Pharma Data

AUGUST 22, 2021

AZD7442 is the first antibody combination (non-vaccine) modified to potentially provide long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial. More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination.

Trials 52

Trials Virus Vaccine Pharmacokinetics 52

PerkinElmer

JUNE 3, 2022

1 Although effective COVID-19 vaccines have been developed, variants of SARS-CoV-2 have already emerged for which vaccines are less effective, and many people remain unvaccinated due to certain medical conditions, personal choice, or global access challenges.

Fragment Screening 52

Fragment Screening Clinical Trials Vaccine Pharmacokinetics 52

The Pharma Data

MAY 7, 2021

The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, and less likely to mutate over time. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines. About the Vir and GSK Collaboration.

Treatment 40

Treatment Virus Vaccine Trials 40

The Pharma Data

MARCH 26, 2021

New in vitro data from pseudotyped virus assays published online in bioRxiv in March 2021 support this hypothesis as they demonstrate that VIR-7831 maintains activity against current circulating variants of concern including the UK, South African and Brazilian variants. About the Vir and GSK Collaboration.

Treatment 52

Treatment FDA Vaccine Trials 52

The Pharma Data

SEPTEMBER 1, 2020

Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with ZEPOSIA. Author: Zhang. Presentation Number: P0343.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

Codon

FEBRUARY 23, 2025

Experimenting with a retrovirus called murine leukemia virus , he found that zidovudine did, in fact, obstruct retrovirus replication by inhibiting reverse transcriptase. A lifelong HIV vaccine would be ideal, but developing one has proved difficult. Subscribe to Asimov Press! Always free. Richly detailed. In South Africa, 12.6

Clinical Trials 76

Clinical Trials Virus Vaccine DNA 76